Build Your Comparison

Side-by-side financial analysis
IVVD logo
IVVD
MNKD logo
MNKD
KO logo
KO
LLY logo
LLY
PEP logo
PEP
Try popular comparisons:

Stock Comparison

IVVD vs MNKD vs KO vs LLY vs PEP

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
IVVD
Invivyd, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$102M
5Y Perf.-97.7%
MNKD
MannKind Corporation

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.13B
5Y Perf.-23.8%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$355.61B
5Y Perf.+46.7%
LLY
Eli Lilly and Company

Drug Manufacturers - General

HealthcareNYSE • US
Market Cap$1.07T
5Y Perf.+338.7%
PEP
PepsiCo, Inc.

Beverages - Non-Alcoholic

Consumer DefensiveNASDAQ • US
Market Cap$197.17B
5Y Perf.-7.7%

IVVD vs MNKD vs KO vs LLY vs PEP — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
IVVD logoIVVD
MNKD logoMNKD
KO logoKO
LLY logoLLY
PEP logoPEP
IndustryBiotechnologyBiotechnologyBeverages - Non-AlcoholicDrug Manufacturers - GeneralBeverages - Non-Alcoholic
Market Cap$102M$1.13B$355.61B$1.07T$197.17B
Revenue (TTM)$56M$361M$49.28B$72.25B$93.92B
Net Income (TTM)$-78M$-24M$13.70B$25.27B$8.24B
Gross Margin92.0%76.0%61.7%83.5%54.1%
Operating Margin-146.4%3.7%29.3%45.9%12.2%
Forward P/E183.0x25.3x30.9x16.7x
Total Debt$2M$473M$45.49B$42.50B$49.90B
Cash & Equiv.$227M$75M$10.27B$7.16B$9.16B

IVVD vs MNKD vs KO vs LLY vs PEPLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

IVVD
MNKD
KO
LLY
PEP
StockAug 21Jun 26Return
Invivyd, Inc. (IVVD)1002.3-97.7%
MannKind Corporation (MNKD)10076.3-23.8%
The Coca-Cola Compa… (KO)100146.7+46.7%
Eli Lilly and Compa… (LLY)100438.7+338.7%
PepsiCo, Inc. (PEP)10092.3-7.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: IVVD vs MNKD vs KO vs LLY vs PEP

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: LLY leads in 4 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. PepsiCo, Inc. is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. IVVD also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇LLY emerged as the overall leader. Track its performance:
IVVD
Invivyd, Inc.
The Growth Leader

IVVD ranks third and is worth considering specifically for growth.

  • 110.5% revenue growth vs KO's 1.9%
Best for: growth
MNKD
MannKind Corporation
The Growth Angle

MNKD lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
KO
The Coca-Cola Company
The Income Angle

Among these 5 stocks, KO doesn't own a clear edge in any measured category.

Best for: consumer defensive exposure
LLY
Eli Lilly and Company
The Growth Play

LLY carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 44.7%, EPS growth 96.0%, 3Y rev CAGR 31.7%
  • 14.8% 10Y total return vs KO's 121.1%
  • Lower volatility, beta 0.53, current ratio 1.58x
  • PEG 1.07 vs PEP's 5.11
Best for: growth exposure and long-term compounding
PEP
PepsiCo, Inc.
The Income Pick

PEP is the #2 pick in this set and the best alternative if income & stability is your priority.

  • Dividend streak 54 yrs, beta -0.11, yield 3.9%
  • Lower P/E (16.7x vs 25.3x)
  • 3.9% yield, 54-year raise streak, vs KO's 2.5%, (2 stocks pay no dividend)
Best for: income & stability
See the full category breakdown
CategoryWinnerWhy
GrowthIVVD logoIVVD110.5% revenue growth vs KO's 1.9%
ValuePEP logoPEPLower P/E (16.7x vs 25.3x)
Quality / MarginsLLY logoLLY35.0% margin vs IVVD's -138.9%
Stability / SafetyLLY logoLLYBeta 0.53 vs IVVD's 2.03
DividendsPEP logoPEP3.9% yield, 54-year raise streak, vs KO's 2.5%, (2 stocks pay no dividend)
Momentum (1Y)LLY logoLLY+40.3% vs IVVD's -9.1%
Efficiency (ROA)LLY logoLLY22.7% ROA vs IVVD's -41.6%, ROIC 41.8% vs -494.9%

IVVD vs MNKD vs KO vs LLY vs PEP — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
IVVDInvivyd, Inc.
FY 2025
Product
100.0%$53M
MNKDMannKind Corporation
FY 2025
Product Revenue
62.0%$217M
Royalty
36.7%$128M
Service
1.2%$4M
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B
LLYEli Lilly and Company
FY 2025
Product
93.5%$61.0B
Collaboration and Other Revenue
6.5%$4.2B
PEPPepsiCo, Inc.

Segment breakdown not available.

IVVD vs MNKD vs KO vs LLY vs PEP — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLLYLAGGINGPEP

Income & Cash Flow (Last 12 Months)

LLY leads this category, winning 4 of 6 comparable metrics.

PEP is the larger business by revenue, generating $93.9B annually — 1681.3x IVVD's $56M. LLY is the more profitable business, keeping 35.0% of every revenue dollar as net income compared to IVVD's -138.9%. On growth, LLY holds the edge at +55.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricIVVD logoIVVDInvivyd, Inc.MNKD logoMNKDMannKind Corporat…KO logoKOThe Coca-Cola Com…LLY logoLLYEli Lilly and Com…PEP logoPEPPepsiCo, Inc.
RevenueTrailing 12 months$56M$361M$49.3B$72.2B$93.9B
EBITDAEarnings before interest/tax-$80M$30M$15.5B$34.7B$14.3B
Net IncomeAfter-tax profit-$78M-$24M$13.7B$25.3B$8.2B
Free Cash FlowCash after capex-$79M$13M$12.6B$13.6B$7.7B
Gross MarginGross profit ÷ Revenue+92.0%+76.0%+61.7%+83.5%+54.1%
Operating MarginEBIT ÷ Revenue-146.4%+3.7%+29.3%+45.9%+12.2%
Net MarginNet income ÷ Revenue-138.9%-6.6%+27.8%+35.0%+8.8%
FCF MarginFCF ÷ Revenue-142.2%+3.5%+25.5%+18.8%+8.2%
Rev. Growth (YoY)Latest quarter vs prior year+21.6%+15.1%+12.1%+55.5%+5.6%
EPS Growth (YoY)Latest quarter vs prior year+7.1%-2.3%+18.2%+169.9%+66.7%
LLY leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

Evenly matched — IVVD and PEP each lead in 3 of 7 comparable metrics.

At 24.0x trailing earnings, PEP trades at a 87% valuation discount to MNKD's 183.0x P/E. Adjusting for growth (PEG ratio), LLY offers better value at 1.71x vs PEP's 7.37x — a lower PEG means you pay less per unit of expected earnings growth.

MetricIVVD logoIVVDInvivyd, Inc.MNKD logoMNKDMannKind Corporat…KO logoKOThe Coca-Cola Com…LLY logoLLYEli Lilly and Com…PEP logoPEPPepsiCo, Inc.
Market CapShares × price$102M$1.1B$355.6B$1.07T$197.2B
Enterprise ValueMkt cap + debt − cash-$122M$1.5B$390.8B$1.11T$237.9B
Trailing P/EPrice ÷ TTM EPS-2.57x183.00x27.18x49.37x24.05x
Forward P/EPrice ÷ next-FY EPS est.25.27x30.95x16.68x
PEG RatioP/E ÷ EPS growth rate2.43x1.71x7.37x
EV / EBITDAEnterprise value multiple29.94x26.39x35.38x16.63x
Price / SalesMarket cap ÷ Revenue1.91x3.24x7.42x16.42x2.10x
Price / BookPrice ÷ Book value/share0.55x10.40x38.34x9.63x
Price / FCFMarket cap ÷ FCF82.60x67.15x119.31x25.70x
Evenly matched — IVVD and PEP each lead in 3 of 7 comparable metrics.

Profitability & Efficiency

LLY leads this category, winning 6 of 9 comparable metrics.

LLY delivers a 101.2% return on equity — every $100 of shareholder capital generates $101 in annual profit, vs $-53 for IVVD. IVVD carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to PEP's 2.43x. On the Piotroski fundamental quality scale (0–9), LLY scores 8/9 vs IVVD's 3/9, reflecting strong financial health.

MetricIVVD logoIVVDInvivyd, Inc.MNKD logoMNKDMannKind Corporat…KO logoKOThe Coca-Cola Com…LLY logoLLYEli Lilly and Com…PEP logoPEPPepsiCo, Inc.
ROE (TTM)Return on equity-53.5%+41.1%+101.2%+40.1%
ROA (TTM)Return on assets-41.6%-3.9%+13.1%+22.7%+7.7%
ROICReturn on invested capital-4.9%+21.6%+15.8%+41.8%+14.9%
ROCEReturn on capital employed-35.8%+8.3%+17.3%+46.6%+16.1%
Piotroski ScoreFundamental quality 0–934785
Debt / EquityFinancial leverage0.01x1.33x1.60x2.43x
Net DebtTotal debt minus cash-$224M$399M$35.2B$35.3B$40.7B
Cash & Equiv.Liquid assets$227M$75M$10.3B$7.2B$9.2B
Total DebtShort + long-term debt$2M$473M$45.5B$42.5B$49.9B
Interest CoverageEBIT ÷ Interest expense0.29x10.70x35.68x10.34x
LLY leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

LLY leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in LLY five years ago would be worth $51,207 today (with dividends reinvested), compared to $369 for IVVD. Over the past 12 months, LLY leads with a +40.3% total return vs IVVD's -9.1%. The 3-year compound annual growth rate (CAGR) favors LLY at 37.2% vs IVVD's -16.0% — a key indicator of consistent wealth creation.

MetricIVVD logoIVVDInvivyd, Inc.MNKD logoMNKDMannKind Corporat…KO logoKOThe Coca-Cola Com…LLY logoLLYEli Lilly and Com…PEP logoPEPPepsiCo, Inc.
YTD ReturnYear-to-date-69.2%-34.6%+20.3%+5.2%+3.5%
1-Year ReturnPast 12 months-9.1%-4.4%+17.2%+40.3%+13.4%
3-Year ReturnCumulative with dividends-40.8%-11.6%+47.0%+158.2%-11.7%
5-Year ReturnCumulative with dividends-96.3%-11.4%+65.6%+412.1%+14.3%
10-Year ReturnCumulative with dividends-96.3%-28.9%+121.1%+1484.6%+82.3%
CAGR (3Y)Annualised 3-year return-16.0%-4.0%+13.7%+37.2%-4.1%
LLY leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

KO leads this category, winning 2 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than IVVD's 2.03 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs IVVD's 25.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricIVVD logoIVVDInvivyd, Inc.MNKD logoMNKDMannKind Corporat…KO logoKOThe Coca-Cola Com…LLY logoLLYEli Lilly and Com…PEP logoPEPPepsiCo, Inc.
Beta (5Y)Sensitivity to S&P 5002.03x1.10x-0.20x0.53x-0.11x
52-Week HighHighest price in past year$3.07$6.51$84.04$1182.73$171.48
52-Week LowLowest price in past year$0.48$2.23$65.35$623.78$127.60
% of 52W HighCurrent price vs 52-week peak+25.1%+56.2%+98.3%+95.8%+84.1%
RSI (14)Momentum oscillator 0–10026.063.760.670.041.6
Avg Volume (50D)Average daily shares traded3.2M5.3M12.7M2.6M6.0M
KO leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Evenly matched — KO and PEP each lead in 1 of 2 comparable metrics.

Analyst consensus: IVVD as "Buy", MNKD as "Buy", KO as "Buy", LLY as "Buy", PEP as "Hold". Consensus price targets imply 1133.8% upside for IVVD (target: $10) vs 4.2% for KO (target: $86). For income investors, PEP offers the higher dividend yield at 3.86% vs LLY's 0.53%.

MetricIVVD logoIVVDInvivyd, Inc.MNKD logoMNKDMannKind Corporat…KO logoKOThe Coca-Cola Com…LLY logoLLYEli Lilly and Com…PEP logoPEPPepsiCo, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyHold
Price TargetConsensus 12-month target$9.50$8.50$86.13$1268.94$167.88
# AnalystsCovering analysts719484545
Dividend YieldAnnual dividend ÷ price+2.5%+0.5%+3.9%
Dividend StreakConsecutive years of raises561154
Dividend / ShareAnnual DPS$2.04$6.00$5.57
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.2%+0.4%+0.5%
Evenly matched — KO and PEP each lead in 1 of 2 comparable metrics.
Key Takeaway

LLY leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). KO leads in 1 (Risk & Volatility). 2 tied.

Best OverallEli Lilly and Company (LLY)Leads 3 of 6 categories
Loading custom metrics...

IVVD vs MNKD vs KO vs LLY vs PEP: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is IVVD or MNKD or KO or LLY or PEP a better buy right now?

For growth investors, Invivyd, Inc.

(IVVD) is the stronger pick with 110. 5% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). PepsiCo, Inc. (PEP) offers the better valuation at 24. 0x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate Invivyd, Inc. (IVVD) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — IVVD or MNKD or KO or LLY or PEP?

On trailing P/E, PepsiCo, Inc.

(PEP) is the cheapest at 24. 0x versus MannKind Corporation at 183. 0x. On forward P/E, PepsiCo, Inc. is actually cheaper at 16. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Eli Lilly and Company wins at 1. 07x versus PepsiCo, Inc. 's 5. 11x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — IVVD or MNKD or KO or LLY or PEP?

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +412.

1%, compared to -96. 3% for Invivyd, Inc. (IVVD). Over 10 years, the gap is even starker: LLY returned +1485% versus IVVD's -96. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — IVVD or MNKD or KO or LLY or PEP?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Invivyd, Inc. 's 2. 03β — meaning IVVD is approximately -1115% more volatile than KO relative to the S&P 500. On balance sheet safety, Invivyd, Inc. (IVVD) carries a lower debt/equity ratio of 1% versus 2% for PepsiCo, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — IVVD or MNKD or KO or LLY or PEP?

By revenue growth (latest reported year), Invivyd, Inc.

(IVVD) is pulling ahead at 110. 5% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to -79. 4% for MannKind Corporation. Over a 3-year CAGR, MNKD leads at 51. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — IVVD or MNKD or KO or LLY or PEP?

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus -98. 2% for Invivyd, Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -104. 0% for IVVD. At the gross margin level — before operating expenses — IVVD leads at 93. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is IVVD or MNKD or KO or LLY or PEP more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Eli Lilly and Company (LLY) is the more undervalued stock at a PEG of 1. 07x versus PepsiCo, Inc. 's 5. 11x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, PepsiCo, Inc. (PEP) trades at 16. 7x forward P/E versus 30. 9x for Eli Lilly and Company — 14. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IVVD: 1133. 8% to $9. 50.

08

Which pays a better dividend — IVVD or MNKD or KO or LLY or PEP?

In this comparison, PEP (3.

9% yield), KO (2. 5% yield), LLY (0. 5% yield) pay a dividend. IVVD, MNKD do not pay a meaningful dividend and should not be held primarily for income.

09

Is IVVD or MNKD or KO or LLY or PEP better for a retirement portfolio?

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

53), 0. 5% yield, +1485% 10Y return). Invivyd, Inc. (IVVD) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LLY: +1485%, IVVD: -96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between IVVD and MNKD and KO and LLY and PEP?

These companies operate in different sectors (IVVD (Healthcare) and MNKD (Healthcare) and KO (Consumer Defensive) and LLY (Healthcare) and PEP (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IVVD is a small-cap high-growth stock; MNKD is a small-cap high-growth stock; KO is a large-cap quality compounder stock; LLY is a mega-cap high-growth stock; PEP is a mid-cap income-oriented stock. KO, LLY, PEP pay a dividend while IVVD, MNKD do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.